Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Bleeding Disorder Referrals to Hematology Clinic: A Single Institution Experience

Oluwaseun Olaiya, DO, Zuri Hudson, DO, Eryn Bilynsky, BSN, RN, CCRC, Hung-Wen Yeh, PhD, Shannon L Carpenter, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140552

Published: 2020

Journal Articles

Patterns and Growth of a Dedicated Pediatric Coagulation Consult Service in a Freestanding Children's Hospital

Shannon L Carpenter, MD, Eryn Bilynsky, BSN, RN, CCRC, Dena Wideman, MSN, ANP, Kristina D'Agostino, MSN, APRN, Lauren E Amos, MD, Mukta Sharma, MD MPH, Michael Silvey, DO

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-139686

Published: 2020

Journal Articles

Acute Airway Obstruction in 4 Pediatric Patients with Congenital Plasminogen Deficiency (C-PLGD) Treated with Intravenous Plasminogen (Human) Replacement Therapy Under an Expanded Access Protocol

Charles Nakar, MD, Neelam Thukral, CCRC, Heather L. McDaniel, MD, Joseph M Parker, MD, Diane Trybul, BS, Amy D Shapiro, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-137177

Published: 2020

Journal Articles

Plasminogen Eye Drops Are Effective in Preventing Recurrence of Pseudomembranes in Ligneous Conjunctivitis: Results from the Phase 2/3 KB046 Trial

Roberto Caputo, MD, Maria Teresa Sartori, MD, Andrea Leonardi, MD, Anna Lotti Suffredini, BSc (Bio), Mirella Calcinai, MD, Roberto Crea, DVM, MSc, Prasad Mathew, MD, Charles Nakar, MD, Neelam Thukral, CCRC, Amy D Shapiro, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-137538

Published: 2020

Journal Articles

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Lynne I. Wagner, PhD, Kathleen Toomey, MD, Sikander Ailawadhi, MD, Sundar Jagannath, Cristina Gasparetto, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, James L. Omel, MD, James W. Hardin, PhD, Hans C. Lee, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Donna Catamero, ANP-BC, OCN, CCRC, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 1843.

https://doi.org/10.1182/blood-2019-126143

Published: 2019

Journal Articles

Cathelicidin Antimicrobial Peptide Expression Is Inversely Associated with Absolute Neutrophil Counts in Pediatric HCT Recipients

Jos Domen, PhD, Hung-Wen Yeh, PhD, Nancy L Shreve, Lei Sun, MD, Yongwu Li, MD, Katrina D Walters, CCRC, Jignesh Dalal, MD, Rakesh K. Goyal, MBBS,MDMRCP

Blood (2019) 134 (Supplement_1): 3294.

https://doi.org/10.1182/blood-2019-131471

Published: 2019

Journal Articles

The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed/Refractory AML and MDS

Justin M Watts, MD, Terrence J Bradley, MD, Amber Thomassen, MA, MSN, Yvonne Trang Dinh, BS, Dalissa Tejera, MSN, Kristen Englund, Sorab Boga, MPH, Randy Astaiza, BS, Charles J Chen, MPH, Malika Abdur-Rahman, BS, MSED, Marinescu Ion, CCRC, FMG, Aymee Perez, PhD, Masoumeh Tayari, PhD, Lluis Morey, PhD, Maria E. Figueroa, MD, Ramin Shiekhattar, PhD, Arthur Zelent, PhD, Ronan Swords, MD PhD

Blood (2018) 132 (Supplement 1): 2721.

https://doi.org/10.1182/blood-2018-99-115411

Published: 2018

Journal Articles

Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Relapsed or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Casey L. O'Connell, MD, Patricia L. Kropf, MD, Nathan Punwani, MD MPH, Dan Rogers, CCRC, CIP, Richard Sposto, PhD, Kirsten Grønbæk, Professor, MD DMSc

Blood (2018) 132 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2018-99-117658

Published: 2018

Journal Articles

A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia

Molly M Gallogly, MDPhD, Ben K. Tomlinson, MD, Pam Bunner, MT, CCRC, Paolo Caimi, MD, Michael Craig, MD, Marcos de Lima, MD, Stanton L. Gerson, MD, Donna Kane, RN, MSN, Hillard M Lazarus, MD, Mark J. Levis, MD, Ehsan Malek, MD, Jane A. Little, MD, Crystal Street, MT, CCRC, Willem J. van Heeckeren, MD PhD, William Tse, MD, Brenda W. Cooper, MD

Blood (2017) 130 (Supplement 1): 1332.

https://doi.org/10.1182/blood.V130.Suppl_1.1332.1332

Published: 2017

Journal Articles

Quantitative Sensory Testing in Children with Sickle Cell Disease

Robin E Miller, MD, Dawn S Brown, PCNS,FNP,CCRC, Sarah E Hegarty, MPhil, Scott W Keith, PhD, Benjamin E Leiby, PhD, Yamaja Setty, PhD, Suhita Gayen-Betal, PhD, Claudia M Campbell, PhD, Marie Stuart, MD

Blood (2017) 130 (Supplement 1): 3541.

https://doi.org/10.1182/blood.V130.Suppl_1.3541.3541

Published: 2017

Journal Articles

Nonmyeloablative (NMA), HLA-Haploidentical (Haplo) Blood or Marrow Transplantation (BMT) from Non-First-Degree Related Donors Has Similar Outcomes to First-Degree Related BMT

Hany Elmariah, MDMS, Yvette L Kasamon, MD, Marianna Zahurak, MS, Noah Tucker, CCRC, Gary Rosner, ScD, F Javier Bolanos-Meade, MD, Ravi Varadhan, PhD, Ephraim J. Fuchs, MD MBA, Amy E. DeZern, MD, Leo Luznik, MD, Richard J. Jones, PhD, Richard F Ambinder, MD

Blood (2017) 130 (Supplement 1): 3304.

https://doi.org/10.1182/blood.V130.Suppl_1.3304.3304

Published: 2017

Journal Articles

Detecting Cases of Monoclonal Gammopathy of Undetermined Significance in Electronic Health Data

Mara M Epstein, ScD, Cassandra Saphirak, MA, Yanhua Zhou, MS, Brenda M Birmann, ScD, Candace Leblanc, BSN, CCRC, Alan G Rosmarin, MD, Jerry H Gurwitz, MD

Blood (2017) 130 (Supplement 1): 3394.

https://doi.org/10.1182/blood.V130.Suppl_1.3394.3394

Published: 2017

Journal Articles

Impact of a Brief Touchscreen Based Modified Geriatric Assessment on the Care of Older Adults with Multiple Myeloma

Nitya Nathwani, Sandra Kurtin, PhD, ANP-C, AOCN, Brea Lipe, MD, Supriya Mohile, MD, Donna D Catamero, ANP-BC, OCN, CCRC, Tanya M. Wildes, MDMSCI, Debra Wujcik, PhD RN, FAAN, Agnes Davis, Laura Digiovanni, MA, Carrie T Stricker, PhD RN, Arti Hurria

Blood (2017) 130 (Supplement 1): 3401.

https://doi.org/10.1182/blood.V130.Suppl_1.3401.3401

Published: 2017

Journal Articles

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Kami J. Maddocks, MD, Jonathon B. Cohen, MD, Ying Huang, MA, MS, Beth A Christian, MD, Don M Benson, MD PhD, Jeffrey Jones, MD MPH, Christopher Flowers, MD MS, Leonard T. Heffner, MD, Cynthia Jenkins, RN, Jennfer Sexton, MHA, CCRC, Alison Neal, MPH, Melissa Kives, MPH, Kristie A. Blum, MD

Blood (2016) 128 (22): 1776.

https://doi.org/10.1182/blood.V128.22.1776.1776

Published: 2016

Journal Articles

Immunotherapeutic Targeting of ROR1-Dependent, Non-Canonical Wnt5a-Signaling By Cirmtuzumab: A First-in-Human Phase I Trial for Patients with Intractable Chronic Lymphocytic Leukemia

Michael Y. Choi, MD, George F. Widhopf, II, PhD, Jian Yu, PhD, Reilly L Kidwell, BS, BA, CCRC, Laura Z. Rassenti, PhD, Charlene Gutierrez, Susette Gorak, Tiffany Juarez, PhD, Emily Pittman, PhD, Hongying Li, PhD, Karen Messer, PhD, Charles Prussak, PhD, Januario E. Castro, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD, PhD

Blood (2016) 128 (22): 3224.

https://doi.org/10.1182/blood.V128.22.3224.3224

Published: 2016

Journal Articles

Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma

Anas Younes, MD, Jesus G. Berdeja, MD, Manish R. Patel, MD, Kevin R. Kelly, MD PhD, Ian W. Flinn, MD PhD, John F Gerecitano, MD PhD, Sattva S. Neelapu, MD, Amanda R. Copeland, RN, MSN, CNS, Amy Akins, RN, BSN, CCRC, Myles Clancy, Anna Ma, MS, Kaiming Sun, PhD, Ze Tian, PhD, Jing Wang, PhD, Jaye Viner, MD MPH, Yasuhiro Oki, MD

Blood (2015) 126 (23): 257.

https://doi.org/10.1182/blood.V126.23.257.257

Published: 2015

Journal Articles

Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts

Michael Y. Choi, MD, George F. Widhopf, II, PhD, Januario Castro, MD, Hongying Li, PhD, Reilly L Kidwell, BS, BA, CCRC, Sam C Zhang, B.A., Tiffany Juarez, PhD, Susette Gorak, Laura Z. Rassenti, PhD, Karen Messer, PhD, Charles Prussak, PhD, Catriona HM Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2015) 126 (23): 1736.

https://doi.org/10.1182/blood.V126.23.1736.1736

Published: 2015

Journal Articles

Re-Induction Outcome for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Therapeutic Advances in Childhood Leukemia Consortium

Weili Sun, MDPhD, Jemily Malvar, MS, Richard Sposto, PhD, Anupam Verma, MD, Jennifer J. Wilkes, MD, Robyn M. Dennis, MD, Kenneth Matthew Heym, MD, Elena Eckroth, CCRC, Jeannette Vandergiesse, BA, CCRP, Paul S. Gaynon, MD, Alan S. Wayne, MD, James A. Whitlock, MD

Blood (2015) 126 (23): 3760.

https://doi.org/10.1182/blood.V126.23.3760.3760

Published: 2015

Journal Articles

The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS

Shannon Somer Stockton, BA, Leslie Pettiford, RN, MS, CCRC, Christina Cline, RN, BSN, David Chaplin, PhD, Jack W Hsu, John R. Wingard, MD, Christopher R. Cogle, MD

Blood (2015) 126 (23): 4936.

https://doi.org/10.1182/blood.V126.23.4936.4936

Published: 2015

Journal Articles

A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia

Blood (2014) 124 (21): 3705.

https://doi.org/10.1182/blood.V124.21.3705.3705

Published: 2014

NARROW

Bleeding Disorder Referrals to Hematology Clinic: A Single Institution Experience

Patterns and Growth of a Dedicated Pediatric Coagulation Consult Service in a Freestanding Children's Hospital

Acute Airway Obstruction in 4 Pediatric Patients with Congenital Plasminogen Deficiency (C-PLGD) Treated with Intravenous Plasminogen (Human) Replacement Therapy Under an Expanded Access Protocol

Plasminogen Eye Drops Are Effective in Preventing Recurrence of Pseudomembranes in Ligneous Conjunctivitis: Results from the Phase 2/3 KB046 Trial

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Cathelicidin Antimicrobial Peptide Expression Is Inversely Associated with Absolute Neutrophil Counts in Pediatric HCT Recipients

The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed/Refractory AML and MDS

Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Relapsed or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia

Quantitative Sensory Testing in Children with Sickle Cell Disease

Nonmyeloablative (NMA), HLA-Haploidentical (Haplo) Blood or Marrow Transplantation (BMT) from Non-First-Degree Related Donors Has Similar Outcomes to First-Degree Related BMT

Detecting Cases of Monoclonal Gammopathy of Undetermined Significance in Electronic Health Data

Impact of a Brief Touchscreen Based Modified Geriatric Assessment on the Care of Older Adults with Multiple Myeloma

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Immunotherapeutic Targeting of ROR1-Dependent, Non-Canonical Wnt5a-Signaling By Cirmtuzumab: A First-in-Human Phase I Trial for Patients with Intractable Chronic Lymphocytic Leukemia

Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma

Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts

Re-Induction Outcome for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Therapeutic Advances in Childhood Leukemia Consortium

The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS

A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only